Henry M. Jackson Foundation

What Henry M. Jackson Foundation does

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a private 501(c)(3) nonprofit founded in 1983 and headquartered in Bethesda, Maryland, with a workforce of 1,001-5,000. HJF provides scientific, administrative, and program operations services that enable medical research for the U.S. Department of Defense, the Uniformed Services University of the Health Sciences (USU), Walter Reed, the Walter Reed Army Institute of Research (WRAIR), the U.S. Army Military Operational Medicine Research Program, AFRIMS, NIAID, and collaborating academic medical centers. Its core services span proposal support, program operations, regulatory compliance, research administration, and research staffing, funded primarily through federal grants, cooperative agreements, and contracts. HJF serves active-duty military, veterans, their families, and civilians by translating military medical research into diagnostics, therapeutics, vaccines, and operational health frameworks.

HJF also operates a technology licensing platform (innovations.hjf.org) and the HJF Innovation Labs incubator in North Bethesda, Maryland, which was opened in March 2026 in partnership with Montgomery County. Its licensable portfolio spans predictive clinical tools (e.g., the WounDx Clinical Decision Support Tool for wound closure probability), diagnostics and therapeutics for ovarian cancer and acute myeloid leukemia, vaccine candidates for malaria, SARS-CoV-2, fentanyl, and pan-coronavirus targets built on a bacterial ferritin nanoparticle platform, and cross-sarbecovirus neutralizing antibodies. Multiple patents are granted or pending across the U.S., EU, UK, France, Germany, Japan, India, Canada, and Australia. The organization is led by President and CEO Joseph Caravalho, Jr., M.D.

Revenue mechanics combine federal research funding (DoD, USU, NIAID) and royalty/license income from its IP portfolio. HJF's GTM is relationship-led and institution-centric, relying on long-standing partnerships with DoD agencies and academic centers, supplemented by licensing to commercial partners and a growing startup incubation channel through HJF Innovation Labs. Brand visibility is reinforced through the annual Heroes of Military Medicine Awards, held in San Antonio and Washington D.C.

Name

Henry M. Jackson Foundation

Legal name

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

Website

https://hjf.org

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Henry M. Jackson Foundation (HJF) is a 501(c)(3) nonprofit, founded in 1983 and based in Bethesda, Maryland, that provides scientific, administrative, and program operations support for U.S. military medical research, licenses military-derived medical technologies, and operates the HJF Innovation Labs incubator for dual-use biotech startups serving active-duty military, veterans, and civilians.

Ownership category

akta.pro rank

Product category

Military Medical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Defense R&D, Test, Evaluation & Innovation (BPAIAHAC)

akta.pro secondary industry

Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery) (HLACAMAL)

Keywords

• Military medical research
• Research administration services
• Biomedical technology licensing
• Vaccine development programs
• Biotech incubator operations

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Research Support Services: HJF provides scientific, administrative, and program operations services to enable medical researchers and clinicians to make discoveries. Revenue comes from grants, cooperative agreements, and service contracts with federal agencies, primarily the Department of Defense.
2. Technology Licensing: HJF licenses its proprietary medical technologies including vaccines, therapeutics, and diagnostics to commercial partners for further development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

HJF provides scientific, administrative, and program operations services to enable military medical researchers and clinicians to make discoveries, including proposal support, program operations, regulatory compliance, research administration, and research staffing. It also develops and licenses proprietary medical innovations — vaccines, therapeutics, diagnostics, biomarkers, and clinical decision support tools — generated through its military medical research collaborations, and operates a regional biotech incubator for dual-use startups.

Product overview

The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) operates as a global nonprofit organization advancing military medicine through a multi-faceted portfolio. HJF provides research solutions services including proposal support, program operations, regulatory compliance, and research staffing. The organization manages the HJF Innovation Labs, a regional biotech incubator in North Bethesda, Maryland for dual-use medical technologies, and the HJF Innovations Technology Platform for licensing military medical innovations. Core licensable technologies include WounDx for wound closure prediction, cancer diagnostics and therapeutics, vaccine candidates including malaria and fentanyl vaccines, and various biomarkers for cancer, infectious diseases, and trauma applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Research Solutions Services Comprehensive research administration services including Proposal Support, Program Operations, Regulatory Compliance, Research Administration, and Research Staffing provided to federal agencies, military commands, and academic medical institutions conducting military medical research.
• HJF Innovation Labs Co-branded regional biotech incubator providing small-scale lab space, shared equipment, wraparound services, and access to global resources including clinical trial sites for early-stage startups developing dual-use military and civilian medical technologies.
• HJF Innovations Technology Platform Online technology licensing and commercialization platform cataloging licensable medical technologies including diagnostics, therapeutics, vaccines, biomarkers, and research tools developed through military medical research.
• WounDx - Predictive Tool on Probability of Successful Wound Closure (HJF 637-22) Clinical Decision Support Tool that analyzes wound healing immune response through cytokine biomarker analysis to predict probability of successful wound closure and reduce dehiscence risk in combat and civilian trauma wounds.
• Diagnostic Tool for High-grade Serous Ovarian Cancer (HJF 616-21) Companion clinical diagnostic assay using orthogonal protein and transcript-based biomarkers correlating with Homologous Recombination Deficiency to prioritize high-grade serous ovarian cancer patients for targeted DNA damage response therapies.
• Small Molecule Therapeutics for Acute Myeloid Leukemia and Solid Tumors (HJF 490-17) Two families of small molecule compounds that specifically block the SETBP1-XPO1 interaction to inhibit tumor cell growth and induce tumor cell differentiation in AML and solid tumors with SETBP1 overexpression or activating mutation.
• Malaria Vaccine (HJF 474-17) Novel malaria vaccine composition containing Plasmodium falciparum circumsporozoite protein immunogen FMP013 formulated with the patented adjuvant ALFQ, with Phase I clinical study demonstrating safety and efficacy.
• Cross-Sarbecovirus Neutralizing Monoclonal Antibodies (HJF 660-23) Six neutralizing monoclonal antibodies with broad sarbecovirus cross-reactivity, intended for developing next-generation vaccine candidates against SARS-CoV-2 and related sarbecoviruses.
• Ly6 Targeted Cancer Immunotherapy (HJF 649-23) Antibodies, antibody-drug conjugates, and CAR transduced immune cells targeting Ly6 family proteins overexpressed in cancer cells.
• Novel Vaccine Enhancers (HJF 642-23) mRNA vaccine improvements that code for antigens and NK cell inhibitors to enhance vaccine durability and reduce side effects.
• Vaccines Against Fentanyl and Fentanyl Analogs (HJF 561-19) Novel fentanyl hapten compounds that induce antibodies with cross-reactivity for fentanyl and fentanyl derivatives.
• Ferritin Nanoparticle Vaccine Platform (HJF 569-20 and HJF 635-22) Bacterial ferritin nanoparticle-based vaccine platform enabling pan-coronavirus vaccines with broad immune responses.
• Peptide Vaccine for Ovarian/Endometrial Cancer (HJF 593-21) Peptide vaccine platform targeting ovarian and endometrial cancer, protected by issued U.S. and European patents.
• Complex Natural Homogenates (HJF 357-13) Worm homogenate compositions for treating allergies and autoimmune diseases, protected by issued patents in multiple jurisdictions.
• Radiation-Protected Protein Compositions (HJF 165-07) Radiation-protected protein compositions protected by seventeen issued patents across multiple jurisdictions, intended to confer protection against radiation exposure.

Quantifiable outcome

• $2 million research award for musculoskeletal injury recovery projects (September 2023 - September 2026)

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability14 records

Feature9 records

Partnerships

15 partnerships are on record, tiered core and major.

• Uniformed Services University of the Health Sciences (USU)coreStrategic or Co-development PartnerLong-standing partnership for collaborative medical research, technology development, and support for military medicine researchers and clinicians.
• Walter Reed Army Institute of Research (WRAIR)coreStrategic or Co-development PartnerCollaborative research on vaccines, therapeutics, and infectious diseases affecting military personnel.
• U.S. Department of DefensecoreStrategic or Co-development PartnerPrimary funding source and research partner for military medicine advancement through various DoD programs and initiatives.
• U.S. Army Military Operational Medicine Research Program (MOMRP)coreStrategic or Co-development PartnerCollaboration on musculoskeletal injury recovery and operational medicine research for Service Members.
• Inova Fairfax Hospital (IFH)majorStrategic or Co-development PartnerCollaborative research on diagnostic tools for ovarian cancer and cancer biomarkers.
• Peter MacCallum Cancer Centre (PMCC)majorStrategic or Co-development PartnerInternational collaboration on cancer research and biomarker development for ovarian cancer diagnostics.
• Montgomery County GovernmentmajorStrategic or Co-development PartnerCo-branded regional biotech incubator (HJF Innovation Labs) for startups developing dual-use military and civilian medical technologies in North Bethesda.
• Duke UniversitymajorStrategic or Co-development PartnerCollaborative research on predicting pulmonary complications following rib fractures using machine learning and biomarkers.
• Oregon Health & Science UniversitymajorStrategic or Co-development PartnerCollaboration on ERG oncoprotein inhibitors and small molecule therapeutics research.
• Leidos Biomedical Research, Inc.majorStrategic or Co-development PartnerCollaboration on mRNA vaccine enhancers and novel vaccine development technologies.
• National Institute of Allergy and Infectious Diseases (NIAID)coreStrategic or Co-development PartnerCollaboration on filarial disease research, vaccine candidates, and infectious disease therapeutics.
• Beth Israel Deaconess Medical Center (BIDMC)majorStrategic or Co-development PartnerCollaboration on ZIKV and DENV neutralizing antibody research and flavivirus vaccine development.
• Armed Forces Research Institute of Medical Sciences (AFRIMS)majorStrategic or Co-development PartnerCollaboration on flavivirus research and neutralizing antibody identification.
• Boston Children's HospitalmajorStrategic or Co-development PartnerCollaboration on prostate cancer gene profiles and racial/ethnic biomarker research.
• University of Maryland, Baltimore (UMB)majorStrategic or Co-development PartnerCollaboration on shark-derived antibodies and nanobodies for SARS-CoV-2 therapeutics and diagnostics.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Battelle Memorial Institute: Large nonprofit scientific research organization managing major federal labs and conducting life sciences, biomedical, and defense research for government clients. Operates under a comparable nonprofit, mission-driven model and contract-research structure as HJF.
• RTI International: Nonprofit research institute delivering scientific, statistical, and engineering R&D services to government and commercial clients, with deep health and biomedical research offerings. Comparable in scale, funding mix (federal grants/contracts), and program operations role.
• Walter Reed Army Institute of Research (WRAIR): Core HJF partner and a DoD biomedical research laboratory conducting infectious disease, vaccine, and combat casualty care research. Directly comparable in mission and research focus; HJF often operates as the administrative backbone for WRAIR investigators.
• PATH: Global nonprofit focused on health innovation, vaccine and diagnostic development, and technology transfer. Closely mirrors HJF's nonprofit R&D, technology licensing, and global health footprint, though with greater emphasis on low-resource settings.
• AAHI (formerly Infectious Disease Research Institute): Nonprofit biotech developing vaccines and immune-based therapies for infectious diseases, including adjuvant and formulation platforms. Directly comparable in vaccine/therapeutic R&D focus, scale, and nonprofit structure.

Broad incumbents

• MITRE Corporation: Federally funded R&D center (FFRDC) operator with deep defense and health portfolios; while broader than HJF, MITRE offers a useful structural parallel as a nonprofit running mission-critical government research programs at scale.
• RAND Corporation: Nonprofit research institution with established defense, health, and policy research practices serving federal sponsors. Shares the nonprofit/government-funded operating model, although its core focus is policy analysis rather than wet-lab science.
• Biomedical Advanced Research and Development Authority (BARDA): U.S. federal authority that funds advanced development of medical countermeasures. While government rather than nonprofit, BARDA addresses the same translational medical R&D mission and competes for similar DoD/HHS research dollars.
• Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership funding vaccine development against epidemic threats; a peer in vaccine R&D funding and coordination, with overlap on cross-sarbecovirus and pan-coronavirus vaccine interests relevant to HJF's portfolio.
• National Center for Advancing Translational Sciences (NCATS): NIH center focused on translational science and moving discoveries from bench to clinic. Adjacent peer given shared translational/clinical development interests and federal alignment, though federally funded rather than nonprofit.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubevimeo.com/user218001085
• LinkedInlinkedin.com/company/hjf
• Xx.com/HJFMilMed

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Henry M. Jackson Foundation